trojanpeptide
GLP-1 Enthusiast
This PDBSN is an interesting compound involved in mitochondrial health. Here is a link to the original publication.
Abstract:
Mitochondria are essential for generating cellular energy and are significant in the pathogenesis of obesity. Human visceral and subcutaneous preadipocytes (HPA-v and HPA-s) were cultured into mature adipocytes. Intracellular triglyceride (TG) content was assessed using oil-red O staining and tissue triglyceride determination. Mitochondrial membrane potential (MMP) and reactiveoxygen species (ROS) levels were measured with fluorescent indicators. Gene and protein expression related to mitochondrial biogenesis were analyzed by real-time quantitative PCR and Western blotting. Morphological changes were observed via electron microscopy. Results show that PDBSN significantly increased MMP while decreasing TG and ROS levels. The transcription and protein levelsof PGC1-α and MTFA were upregulated, and mitochondrial fusion and fission markers (MFN1, MFN2, NRF1, DRP1) were elevated. Additionally, PDBSN enhanced maximumrespiratory capacity and reduced ROS. These findings suggest that PDBSN improves mitochondrial function, providing insights for obesity treatment and metabolic disease management.
The PDBSN peptide is explicitly defined in the literature as a 15‑amino‑acid sequence: GLSVADLAESIMKNL. This comes directly from the paper that first characterizes it as an anti‑adipogenic peptide, where it is named and the sequence given as “a novel peptide, PDBSN (GLSVADLAESIMKNL), that could significantly restrict adipocyte differentiation in vitro” (Shen et al., 2020). The earlier mechanistic work describes PDBSN as a “novel peptide PDBSN” that suppresses adipogenesis via AMPK activation, but in that abstract PDBSN is not spelled out; the sequence is instead provided in the later liposome‑encapsulation study (Shen et al., 2019).
Shen, D., Gao, J., Xia, J., Wang, X., Zhou, Y., Chen, L., Xu, L., & Guo, X. (2020). Liposome-encapsulated peptide PDBSN ameliorates high-fat-diet-induced obesity and improves metabolism homeostasis.. Biochemical and biophysical research communications. https://doi.org/10.1016/j.bbrc.2020.09.014
Shen, D., Li, Y., Wang, X., Wang, F., Huang, F., Cao, Y., You, L., Wen, J., Wang, Y., Cui, X., Ji, C., & Guo, X.-R. (2019). A novel peptide suppresses adipogenic differentiation through activation of the AMPK pathway.. Biochemical and biophysical research communications, 510 3, 395-402. https://doi.org/10.1016/j.bbrc.2019.01.112
Seems like a nice research molecule for sure.
Abstract:
Mitochondria are essential for generating cellular energy and are significant in the pathogenesis of obesity. Human visceral and subcutaneous preadipocytes (HPA-v and HPA-s) were cultured into mature adipocytes. Intracellular triglyceride (TG) content was assessed using oil-red O staining and tissue triglyceride determination. Mitochondrial membrane potential (MMP) and reactiveoxygen species (ROS) levels were measured with fluorescent indicators. Gene and protein expression related to mitochondrial biogenesis were analyzed by real-time quantitative PCR and Western blotting. Morphological changes were observed via electron microscopy. Results show that PDBSN significantly increased MMP while decreasing TG and ROS levels. The transcription and protein levelsof PGC1-α and MTFA were upregulated, and mitochondrial fusion and fission markers (MFN1, MFN2, NRF1, DRP1) were elevated. Additionally, PDBSN enhanced maximumrespiratory capacity and reduced ROS. These findings suggest that PDBSN improves mitochondrial function, providing insights for obesity treatment and metabolic disease management.
The PDBSN peptide is explicitly defined in the literature as a 15‑amino‑acid sequence: GLSVADLAESIMKNL. This comes directly from the paper that first characterizes it as an anti‑adipogenic peptide, where it is named and the sequence given as “a novel peptide, PDBSN (GLSVADLAESIMKNL), that could significantly restrict adipocyte differentiation in vitro” (Shen et al., 2020). The earlier mechanistic work describes PDBSN as a “novel peptide PDBSN” that suppresses adipogenesis via AMPK activation, but in that abstract PDBSN is not spelled out; the sequence is instead provided in the later liposome‑encapsulation study (Shen et al., 2019).
Shen, D., Gao, J., Xia, J., Wang, X., Zhou, Y., Chen, L., Xu, L., & Guo, X. (2020). Liposome-encapsulated peptide PDBSN ameliorates high-fat-diet-induced obesity and improves metabolism homeostasis.. Biochemical and biophysical research communications. https://doi.org/10.1016/j.bbrc.2020.09.014
Shen, D., Li, Y., Wang, X., Wang, F., Huang, F., Cao, Y., You, L., Wen, J., Wang, Y., Cui, X., Ji, C., & Guo, X.-R. (2019). A novel peptide suppresses adipogenic differentiation through activation of the AMPK pathway.. Biochemical and biophysical research communications, 510 3, 395-402. https://doi.org/10.1016/j.bbrc.2019.01.112
Seems like a nice research molecule for sure.